BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Fiera Capital Corp trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters -- they're not just another dose of ...

Arcturus Therapeutics (ARCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...